SCHEMBL4173548

SCHEMBL4173548

CN(C)c1ccc(NC(=O)Cn2ccnc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.56
MAPT P10636 4/20 0.53
ALDH1A1 P00352 4/20 0.53
LMNA P02545 1/20 0.53
KDM4E B2RXH2 1/20 0.52
AHR P35869 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MGLL Q99685 1/20 0.52
HPGD P15428 1/20 0.51
TSHR P16473 1/20 0.49
NR4A1 P22736 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
ESR2 Q92731 1/20 0.49
MCL1 Q07820 1/20 0.48
RAB9A P51151 1/20 0.48
GFER P55789 1/20 0.48
TBXAS1 P24557 1/20 0.47
GAA P10253 1/20 0.47
IDE P14735 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17675670 0.84 MGLL (0.57) ALDH1A1KDM4EAHRNPSR1MGLL
SCHEMBL21076446 0.82 MGLL (0.62) QPCTALDH1A1KDM4EAHRNPSR1
SCHEMBL30443118 0.81 CYP19A1 (0.64) QPCTALDH1A1LMNAKDM4EAHR
SCHEMBL13182159 0.81 CYP1A2 (0.60) QPCTALDH1A1KDM4EAHRNPSR1
SCHEMBL1355046 0.81 MGLL (0.55) ALDH1A1KDM4EAHRNPSR1MGLL
SCHEMBL29218586 0.81 ALDH1A1 (0.56) MAPTALDH1A1LMNAKDM4EAHR
SCHEMBL1355808 0.80 MGLL (0.54) ALDH1A1KDM4EAHRNPSR1MGLL
SCHEMBL19827074 0.78 MGLL (0.53) MAPTALDH1A1KDM4EAHRNPSR1
SCHEMBL19827068 0.77 TBXAS1 (0.51) QPCTALDH1A1KDM4EAHRNPSR1
SCHEMBL10855916 0.76 ALDH1A1 (0.73) MAPTALDH1A1LMNAKDM4EAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023735-A1 Sulphonamide Derivatives BIOTIE THERAPIES CORP. (FI) 2009-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023735-A1 Sulphonamide Derivatives HCAR1, ADGRE5, ALK QPCT 3071/4885MAPT 4881/4885ALDH1A1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.